[The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
Olsen
Jens
J
Syddansk Universitet, Center for Anvendt Sundhedstjenesteforskning og Teknologivurdering, og. jeo@cast.sdu.dk
Gundgaard
Jens
J
Borris
Lars Carl
LC
D000925:Anticoagulants / Q000008:administration & dosage* / Q000191:economics; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects*; D019645:Arthroplasty, Replacement, Knee / Q000009:adverse effects*; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D003657:Decision Making; D003718:Denmark; D016527:Drug Costs; D017984:Enoxaparin / Q000008:administration & dosage* / Q000191:economics; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000191:economics; D000077425:Fondaparinux; D006801:Humans; D018803:Models, Economic; D011134:Polysaccharides / Q000008:administration & dosage* / Q000191:economics; D011183:Postoperative Complications / Q000517:prevention & control*; D011655:Pulmonary Embolism / Q000209:etiology / Q000517:prevention & control; D012307:Risk Factors; D020246:Venous Thrombosis / Q000209:etiology / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D011134:Polysaccharides; D000077425:Fondaparinux